Webinar: Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics (2020)

September 1, 2020

Course Director:  Kelly L. Stratton, MD

This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting.

Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.


This educational activity is supported by independent educational grants from:

  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Genentech
  • Merck
  • Pfizer, Inc.
  • Sanofi Genzyme

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
  2. Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients.
  3. Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.
  4. Describe advances in genomic testing and personalized medicine for urologic cancers.
  5. Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
09/01/2020 - 7:00pm
Event ends: 
09/01/2020 - 8:30pm

Scientific Agenda

Welcome & Housekeeping



AUA/Kelly Stratton, MD

Faculty and Course Introduction

Kelly Stratton, MD

Associate Professor of Urologic Oncology

University of Oklahoma, Stephenson Cancer Center

Multi-Disciplinary Approach to Prostate Cancer

Alicia Morgans, MD, MPH

Associate Professor of Medicine, Division of Hematology/Oncology

Northwestern University Feinberg School of Medicine

Multidisciplinary Care for Metastatic Castrate Resistant Prostate Cancer

Kelvin A. Moses, MD, PhD, FACS

Associate Professor of Urology

Vanderbilt University Medical Center

Adjuvant treatments and Multidisciplinary Management of mRCC

Brian Shuch, MD

Associate Professor of Urology

Director, UCLA Kidney Cancer Program

Multidisciplinary Care for Bladder Cancer

Kelly Stratton, MD


All Faculty

Wrap Up/Reminders

Kelly Stratton, MD/AUA

Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics (2020) will be held virtually on Tuesday, September 1 at 7 PM EST.


  1. Click the "Register" tab.
  2. If prompted, click “update your profile”. Otherwise, click “Take Course”.
  3. Click “Start” under Live Webinar in the Course Progress pane.
  4. Click "Join Webinar".

Education Council Disclosures

PDF icon Education Council & COI Reviewer Disclosure_090120.pdf

AUA Office of Education Staff has nothing to disclose.



The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA Participant Information and Policies


The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.


The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meetings.


Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.


The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Non-Physician Participation
Please login or register to take this course.

To join the webinar, click here: Access Webinar